Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.

Provost C, Prignon A, Cazes A, Combaret V, Delattre O, Janoueix-Lerosey I, Montravers F, Talbot JN.

Anticancer Res. 2016 Sep;36(9):4459-66.

PMID:
27630282
2.

Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.

Kiviniemi A, Gardberg M, Autio A, Li XG, Heuser VD, Liljenbäck H, Käkelä M, Sipilä H, Kurkipuro J, Ylä-Herttuala S, Knuuti J, Minn H, Roivainen A.

Acta Oncol. 2014 Aug;53(8):1125-34. doi: 10.3109/0284186X.2014.925577. Epub 2014 Jun 24.

PMID:
24957558
3.
4.

Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.

Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):823-30. Epub 2006 Mar 29.

PMID:
16570185
5.

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A.

Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52. doi: 10.1007/s00259-008-0944-5. Epub 2008 Sep 20.

PMID:
18807033
6.

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.

Zhang L, Vines DC, Scollard DA, McKee T, Komal T, Ganguly M, Do T, Wu B, Alexander N, Vali R, Shammas A, Besanger T, Baruchel S.

Contrast Media Mol Imaging. 2017 Aug 8;2017:9481276. doi: 10.1155/2017/9481276. eCollection 2017.

7.

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.

Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U.

Theranostics. 2018 May 23;8(12):3380-3391. doi: 10.7150/thno.24017. eCollection 2018.

8.

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1115-22. Epub 2006 Jun 9.

PMID:
16763820
9.

⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.

Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, Virgolini IJ, Riechelmann H, Rasse M, Waitz D, Putzer D.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1365-72. doi: 10.1007/s00259-013-2442-7. Epub 2013 May 18.

PMID:
23685751
10.

In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirrmacher R, Wängler B.

J Nucl Med. 2015 Jul;56(7):1100-5. doi: 10.2967/jnumed.114.149583. Epub 2015 May 14.

12.

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2015 Jun;17(3):313-8. doi: 10.1007/s11307-014-0795-3.

PMID:
25319765
13.

Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.

Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo MÁ, Desco M.

PLoS One. 2014 Nov 4;9(11):e111624. doi: 10.1371/journal.pone.0111624. eCollection 2014.

14.

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.

J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30.

15.

Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.

Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, Dutta R.

Cancer Imaging. 2011 Jun 15;11:70-5. doi: 10.1102/1470-7330.2011.0010.

16.

Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.

Eur Radiol. 2011 Nov;21(11):2408-16. doi: 10.1007/s00330-011-2199-y. Epub 2011 Jul 13.

PMID:
21750886
17.

Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.

Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):76-83.

18.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

19.

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.

Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H.

Eur J Nucl Med. 2001 Dec;28(12):1751-7. Epub 2001 Oct 31.

PMID:
11734911
20.

Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma.

Brogsitter C, Zöphel K, Wunderlich G, Kämmerer E, Stein A, Kotzerke J.

Nucl Med Commun. 2013 Jan;34(1):47-9. doi: 10.1097/MNM.0b013e32835ae4ed.

PMID:
23111377

Supplemental Content

Support Center